SecBot SecBot

AZTR drug pipeline

Azitra, Inc. · 3 rated drugs
$0.6090
−2.9% 1-day · Nov 17
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.9%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
3
1 bearish · 2 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 1/2
Time to marketUnknown — at least 3-5 years if Phase 1/2 data is positive, followed by Phase 3 trials and FDA review. The Fast Track designation could accelerate the timeline.

ATR-04 atr04-484 Updated Sep 12

What to watch

Watch for ATR-04 Phase 1/2 first-cohort topline data expected Q4 2026, positive safety/efficacy signals could drive a sharp rally given the tiny market cap, but the ~6-month cash runway means a dilutive financing is likely before year-end regardless of results. The stock is a high-risk binary play on a single early-stage asset.

Bull case
  • FDA Fast Track designation signals regulatory interest and potential for accelerated development for an unmet need (EGFRi rash affects ~150,000 US patients annually)
  • Analyst consensus is strongly bullish: 6 Buy/Strong Buy vs 1 Hold, with mean price target of $0.775 (~335% upside from $0.18) and Maxim Group maintaining Buy at $4
  • Institutional accumulation: UBS Group added (+67% shares) and Citigroup doubled (+261%) their positions in Q2 2026
Bear case
  • Cash runway of only ~6 months ($6.7M as of June 30, 2026) with a quarterly burn of ~$3.3M, dilutive financing is highly likely before year-end
  • ATR-12 Netherton Syndrome trial was paused to conserve cash, signaling capital constraints and pipeline prioritization risk
  • Phase 1/2 trial is very early stage, safety/efficacy data from a small first cohort may not be statistically meaningful or may reveal safety issues
◆ mixed
Impact
PhasePreclinical / Ex Vivo
Time to marketAs a cosmetic product, ATR-COSF does not require FDA drug approval but must comply with FDA cosmetic regulations. If first-in-human results are positive, the earliest potential commercialization would likely be 12-24 months away, depending on formulation development, safety testing, and manufacturing scale-up.

ATR-COSF Updated Nov 11

What to watch

The next catalyst for ATR-COSF is initial first-in-human study results, anticipated by year-end 2026 (approximately 6-7 weeks from today). Positive results could validate the platform for cosmetic applications and open a path to market, while negative or underwhelming results would be a setback for this early-stage program. The stock also has other catalysts from the ATR-04 Phase 1/2 trial (advancing to Cohort 2) and potential ATR-12 updates.

Bull case
  • Positive ex vivo data shows single-dose fine-line reduction of approximately 50% at 48 hours and improved skin elasticity, providing proof of concept for the filaggrin-based approach.
  • First-in-human results expected by year-end 2026 (within weeks) could serve as a near-term catalyst for the stock.
  • ATR-COSF leverages Azitra's microbial genetic engineering platform, which could be applied to additional cosmetic and therapeutic proteins.
Bear case
  • ATR-COSF has only ex vivo data so far; no human safety or efficacy data has been released, making the upcoming first-in-human results a high-risk binary event.
  • Azitra is a micro-cap stock trading near $0.60 with a 52-week low of $0.52, recently executed a 1-for-10 reverse stock split, and has an NYSE American compliance plan to meet minimum equity requirements by April 2027.
  • The cosmetic anti-aging market is highly competitive with many established products and brands, making differentiation and market share challenging even if the product works.
▼ bearish
Impact
PhasePhase 1b
Time to marketUnknown — the trial is paused with no disclosed timeline for resumption. Even if restarted, a Phase 1b trial would need to complete before advancing to later-stage studies, putting potential approval years away.

ATR-12 Updated Sep 12

What to watch

ATR-12 has no near-term catalyst since enrollment is paused. Watch Azitra's other programs (ATR-COSF cosmetic study expected late 2026, ATR-04 topline data expected Q4 2026) for potential stock-moving events, but the primary risk is dilutive financing given the ~6-month cash runway and $2-3M market cap.

Bull case
  • If Azitra's financial position improves (via partnership, warrant exercise, or equity raise), ATR-12 enrollment could resume, offering a path to treat a rare disease with no approved therapies.
  • Netherton Syndrome is a serious, underserved rare disease, if ATR-12 eventually generates positive data, it could command significant orphan drug pricing.
Bear case
  • ATR-12 enrollment is paused indefinitely, the company explicitly stated it paused the trial to conserve capital, meaning the program is deprioritized with no timeline for restart.
  • Azitra had only ~$6.7M in cash as of June 30, 2026, with a quarterly burn rate of ~$3.3M, implying ~6 months of runway, severe risk of dilutive financing or bankruptcy before ATR-12 could resume.
  • An S-1 registration effective June 2026 covers resale of up to 255.7M shares (526% of outstanding), creating massive overhang that caps any upside.

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Mar 13, 2026ATR-04Fast Track−10.1%+57.1%
Dec 31, 2025ATR-04Fast Track+1.7%+10.9%